MD-1 | A NF-κB1 p105 Degrader

MedKoo Cat#: 128949 | Name: MD-1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MD-1 is a NF-κB1 p105 Degrader for Anti-Inflammatory Therapy. MD-1 is a degrader of the p105 subunit of NF-κB. Gene knockdown experiments further showed that the Cullin-ring ligase (CRL) SCFβTrCP is involved in MD-1-induced p105 degradation. This leads to suppressed NF-κB transcriptional activity, which is consistent with its potent anti-inflammatory effects.

Chemical Structure

MD-1

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 128949

Name: MD-1

CAS#: N/A

Chemical Formula: C21H18O4

Exact Mass: 334.1205

Molecular Weight: 334.37

Elemental Analysis: C, 75.43; H, 5.43; O, 19.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MD-1; MD1; MD 1

IUPAC/Chemical Name

6-methoxy-8-(3-methylbut-2-enoyl)-3-phenyl-2H-chromen-2-one

InChi Key

NJUGMKGTBSDZGY-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H18O4/c1-13(2)9-19(22)18-12-16(24-3)10-15-11-17(21(23)25-20(15)18)14-7-5-4-6-8-14/h4-12H,1-3H3

SMILES Code

COC1=CC(C(/C=C(C)/C)=O)=C(OC(C(C2=CC=CC=C2)=C3)=O)C3=C1

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kimoto M, Nagasawa K, Miyake K. Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scand J Infect Dis. 2003;35(9):568-72. doi: 10.1080/00365540310015700. PMID: 14620136. 2: Schultz TE, Blumenthal A. The RP105/MD-1 complex: molecular signaling mechanisms and pathophysiological implications. J Leukoc Biol. 2017 Jan;101(1):183-192. doi: 10.1189/jlb.2VMR1215-582R. Epub 2016 Apr 11. PMID: 27067450. 3: Thomas Jennings R, Odkhuu E, Nakashima A, Morita N, Kobayashi T, Yamai I, Tanaka M, Suganami T, Haga S, Ozaki M, Watanabe Y, Nagai Y, Takatsu K, Kikuchi- Ueda T, Ichimonji I, Ogawa Y, Takagi H, Yamazaki T, Miyake K, Akashi-Takamura S. Inflammatory responses increase secretion of MD-1 protein. Int Immunol. 2016 Oct;28(10):503-512. doi: 10.1093/intimm/dxw031. Epub 2016 Jun 28. PMID: 27352793. 4: Biswas M, Yamazaki T, Tomono S, Karnan S, Takagi H, Ichimonji I, Inui M, Nagaoka F, Hosokawa Y, Akashi-Takamura S. Cell surface expression of human RP105 depends on N-glycosylation of MD-1. FEBS Lett. 2022 Dec;596(24):3211-3231. doi: 10.1002/1873-3468.14452. Epub 2022 Jul 28. PMID: 35849076. 5: Zhang YJ, Huang H, Liu Y, Kong B, Wang G. Retracted: MD-1 Deficiency Accelerates Myocardial Inflammation and Apoptosis in Doxorubicin-Induced Cardiotoxicity by Activating the TLR4/MAPKs/Nuclear Factor kappa B (NF-κB) Signaling Pathway. Med Sci Monit. 2024 May 22;30:e945188. doi: 10.12659/MSM.945188. PMID: 38775003; PMCID: PMC11129601. 6: Pan H, Zhang G, Zhang L, Wang W, Shang J, Wang X, Zhao Q, Li J. MD-1 deficiency attenuates dextran sodium sulfate (DSS)-induced colitis through modulating the function of colonic lamina propria dendritic cells. Mol Immunol. 2016 Jul;75:1-10. doi: 10.1016/j.molimm.2016.05.008. Epub 2016 May 19. PMID: 27209086. 7: Edwards K, Manoussaka M, Sayed U, Tsertsvadze T, Deyn L, Nathwani A, Gribben JG, Krysov S, Volpi EV, Lydyard PM, Porakishvili N. MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL. Leuk Res. 2024 Aug;143:107540. doi: 10.1016/j.leukres.2024.107540. Epub 2024 Jun 11. PMID: 38897026. 8: Zhang YJ, Huang H, Liu Y, Kong B, Wang G. MD-1 Deficiency Accelerates Myocardial Inflammation and Apoptosis in Doxorubicin-Induced Cardiotoxicity by Activating the TLR4/MAPKs/Nuclear Factor kappa B (NF-κB) Signaling Pathway. Med Sci Monit. 2019 Oct 22;25:7898-7907. doi: 10.12659/MSM.919861. Retraction in: Med Sci Monit. 2024 May 22;30:e945188. doi: 10.12659/MSM.945188. PMID: 31636246; PMCID: PMC6820359. 9: Sasaki S, Nagai Y, Yanagibashi T, Watanabe Y, Ikutani M, Kariyone A, Tsuneyama K, Hirai Y, Takatsu K. Serum soluble MD-1 levels increase with disease progression in autoimmune prone MRL(lpr/lpr) mice. Mol Immunol. 2012 Jan;49(4):611-20. doi: 10.1016/j.molimm.2011.10.008. Epub 2011 Nov 25. PMID: 22118968.